Clinical Trial Update: SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SCRT + mFOLFOX6 + PD-1 inhibitor + targeted therapy for high-risk microsatellite-stable rectal cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)
• SCRT (short-course radiotherapy)
• Targeted therapy
• mFOLFOX6 regimen

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Status: RECRUITING